Valeant has another asset sale in the works

Valeant Pharmaceuticals may sell its eye surgery equipment business, according to Dow Jones.

Talks are still in their preliminary stages, but the business could sell for as much as $2.5 billion.

On Tuesday the company announced that it is in talks to sell one of its core businesses, Salix, to Takeda for $10 billion.

The beleaguered company is trying to sell assets to bring down its over $30 billion in debt.

More on this to come…

NOW WATCH: Wells Fargo CEO John Stumpf is retiring, effective immediately

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at